SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 233 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,412,769 | +34.8% | 51,243 | +47.0% | 0.00% | +100.0% |
| Q2 2023 | $1,048,222 | +86.2% | 34,871 | +124.4% | 0.00% | 0.0% |
| Q1 2023 | $563,050 | +6.9% | 15,541 | +5.2% | 0.00% | 0.0% |
| Q4 2022 | $526,845 | -74.3% | 14,770 | -75.6% | 0.00% | -66.7% |
| Q3 2022 | $2,051,000 | +7.1% | 60,591 | -8.5% | 0.00% | +50.0% |
| Q2 2022 | $1,915,000 | -34.9% | 66,212 | -39.9% | 0.00% | -33.3% |
| Q3 2021 | $2,940,000 | -52.6% | 110,227 | -45.3% | 0.00% | -57.1% |
| Q2 2021 | $6,204,000 | +185.2% | 201,488 | +142.5% | 0.01% | +133.3% |
| Q1 2021 | $2,175,000 | +10.1% | 83,094 | +5.8% | 0.00% | 0.0% |
| Q4 2020 | $1,976,000 | +51.8% | 78,520 | +25.7% | 0.00% | +50.0% |
| Q3 2020 | $1,302,000 | -7.7% | 62,488 | +5.2% | 0.00% | 0.0% |
| Q2 2020 | $1,411,000 | +215.0% | 59,395 | +214.8% | 0.00% | +100.0% |
| Q4 2019 | $448,000 | +8.5% | 18,868 | +25.6% | 0.00% | 0.0% |
| Q3 2019 | $413,000 | -19.8% | 15,027 | -3.4% | 0.00% | 0.0% |
| Q2 2019 | $515,000 | +8.6% | 15,559 | +15.1% | 0.00% | 0.0% |
| Q1 2019 | $474,000 | -55.6% | 13,523 | -57.9% | 0.00% | -66.7% |
| Q4 2018 | $1,068,000 | -77.2% | 32,141 | -65.5% | 0.00% | -66.7% |
| Q3 2018 | $4,690,000 | +1.8% | 93,140 | +21.1% | 0.01% | -10.0% |
| Q2 2018 | $4,605,000 | +185.0% | 76,938 | +118.1% | 0.01% | +150.0% |
| Q1 2018 | $1,616,000 | -4.7% | 35,280 | -17.1% | 0.00% | 0.0% |
| Q4 2017 | $1,696,000 | -24.8% | 42,559 | -24.5% | 0.00% | -33.3% |
| Q3 2017 | $2,255,000 | +24.2% | 56,376 | -2.8% | 0.01% | +20.0% |
| Q1 2017 | $1,816,000 | -5.3% | 58,029 | -23.6% | 0.01% | -16.7% |
| Q4 2016 | $1,917,000 | +682.4% | 75,918 | +666.2% | 0.01% | +500.0% |
| Q3 2016 | $245,000 | +20.1% | 9,908 | -0.9% | 0.00% | 0.0% |
| Q2 2016 | $204,000 | -67.9% | 10,000 | -76.0% | 0.00% | -50.0% |
| Q1 2016 | $635,000 | -71.5% | 41,628 | -74.9% | 0.00% | -66.7% |
| Q4 2015 | $2,226,000 | -19.3% | 165,645 | -15.8% | 0.01% | -25.0% |
| Q3 2015 | $2,760,000 | – | 196,690 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |